| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
We aimed to explore a new treatment strategy for prostaglandin inhibitor-resistant patent ductus arteriosus in preterm infants. Glucocorticoid is a major anti-inflammatory drug, and some observational studies have demonstrated that the prevalence of patent ductus arteriosus is lower in human preterm infants who received antenatal betamethasone. In the present study, we demonstrated that betamethasone promoted migration of smooth muscle cells isolated from rat preterm ductus arteriosus via Art3 and antenatal administration of betamethasone enhanced intimal thickening formation in preterm rat ductus arteriosus. These data suggest the beneficial role of antenatal betamethasone in the closure of preterm ductus arteriosus.
|
